Article
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2025
Sun Hongfu, Li Minghao, Huang Wei, Zhang Jian, Wei Shihong, Yang Yongjing, Wang Zhongtang, Ye Shucheng, Gong Heyi, Zhang Yaowen, Li Jie, Song Haixia, Wang Lifang, Chen Xiangming, Lin Haiqun, Ding Gaofeng, Li Hongwei, Zheng Anping, Ma Xuezhen, Chen ShaoShui, Liu Liping, Zhang Kaixian, Fu Chengrui, Liu Wenzhi, Wang Jing, Zhang Xiaqin, Liu Tingting, Han Dan, Zhao Qian, Wu Peipei, Yuan Qianqian, Tian LiJun, Zhang Ping, Wu Xueqin, Chen Fei, Zhang Zicheng, Li Baosheng
Abstract excerpt
PURPOSE: This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors (TKIs), compared with TKIs alone, could...
Topics
Join the communities discussing this publication.